Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

PanFlu Pandemic Preparedness Through Intranasal Administration of Broadly Effective Monoclonal Antibodies Against All Influenza Strains

Coordinator
Leyden Laboratories BV, Netherlands
Runs
1 November 2025 to 31 October 2027
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101218680

What the project is doing

In the project's own words, from its summary on CORDIS.

Respiratory infectious diseases pose a significant threat to global health, spreading rapidly and hindering containment. The COVID-19 pandemic, with over 450 million cases in two years, highlighted the need for effective preventive measures beyond vaccines and antivirals, which have notable limitations. Leyden Labs is pioneering a groundbreaking platform to counter evolving viral threats with nasal sprays developed using the world's most broadly neutralizing anti-influenza antibody (name disclosed in the short proposal).

Our technology features high-affinity binding antibodies targeting the virus to prevent immune escape, with intranasal delivery ensuring targeted protection at the infection site for enhanced efficacy and convenience. Our primary market is EU healthcare providers, working closely with EU health authorities for effective pandemic response. Success in the EU will pave the way for global expansion, including the US market.

Our nasal sprays will be available by prescription and through government partnerships, with revenue from insurance coverage and government contracts. This innovative platform aims to significantly improve pandemic preparedness and global health security. EU funding is crucial for financial support and strategic collaborations with EU healthcare providers, positioning us as leaders in healthcare innovation. The 2024 EIC Accelerator challenge will support the development of broad-spectrum monoclonal antibody-based therapeutics, ensuring efficacy against resistant variants.

Topics

Who is involved

OrganisationCityCountryRole
Leyden Laboratories BVLeidenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI